The audited report on Sopharma 2025 consolidated financials disclosed a number of corrections, which resulted in reducing net income by 3.3% compared to preliminary figure. The most notable adjustment was the increase of income tax provisions by 37.8%. 2025 sales grew 22.6% YoY to BGN 2.6bn, EBITDA increased 55.3% YoY to BGN 219.2m, reflecting positive developments across all segments, and net income surged 69.3% YoY to BGN 129.2m (EPS BGN 0.25).